US-12616766-B2 - Clostridiodes difficile growth inhibitor

Abstract

Provided is a growth inhibitor for Clostridioides difficile . A growth inhibitor for Clostridioides difficile , comprising killed Enterococcus faecalis . Also provided are a parenteral pharmaceutical preparation, a bactericide, a disinfectant, an antibacterial agent, a sanitizer or a detergent for inhibiting the growth of Clostridioides difficile.

Inventors

• Susumu Kawaguchi

Assignees

• NUTRI CO., LTD.

Dates

Publication Date

20260505

Application Date

20210308

Priority Date

20200313

Claims (20)

1. 1 . A method of reducing growth of Clostridioides difficile , the method comprising applying killed Enterococcus faecalis to an object, wherein the object is an antibacterial product comprising at least one selected from the group consisting of antibacterial towels, antibacterial plastic tableware, antibacterial toys, antibacterial PC-related products, and antibacterial stationery; or the object comprises at least one selected from the group consisting of gauze, absorbent cotton, alcohol swab, cotton swab, bandage, mask, gloves, adhesive plaster, surgical tape, bed & bath supplies, wet wipes, wet towel, soap, and coagulant for excrement.
2. 2 . The method according to claim 1 , wherein the killed Enterococcus faecalis is prepared as a liquid suspension.
3. 3 . The method according to claim 2 , wherein the liquid suspension comprises 0.6% by mass or more of the killed Enterococcus faecalis.
4. 4 . The method according to claim 2 , wherein the liquid suspension further comprises at least one selected from the group consisting of glycerin, caprylic acid monoglyceride, ethanol, and purified water.
5. 5 . The method according to claim 2 , wherein the liquid suspension is used as a spray.
6. 6 . The method according to claim 2 , wherein the liquid suspension is soaked in an absorbent material to prepare a sanitizing wipe.
7. 7 . The method according to claim 1 , wherein the killed Enterococcus faecalis is EF-2001 strain.
8. 8 . The method according to claim 1 , wherein the killed Enterococcus faecalis is prepared as a bactericide, a disinfectant, an antibacterial agent, a sanitizer, or a detergent.
9. 9 . The method according to claim 1 , wherein the killed Enterococcus faecalis is prepared as an agent comprising 0.6% by mass or more of the killed Enterococcus faecalis.
10. 10 . A method of reducing growth of Clostridioides difficile , the method comprising applying killed Enterococcus faecalis , wherein applying the killed Enterococcus faecalis comprises externally administering a pharmaceutically effective amount of the killed Enterococcus faecalis to a subject in need thereof.
11. 11 . The method according to claim 10 , wherein the subject is a human.
12. 12 . The method according to claim 10 , wherein the killed Enterococcus faecalis is administered topically.
13. 13 . The method according to claim 10 , wherein the killed Enterococcus faecalis is prepared as a transdermal patch.
14. 14 . The method according to claim 10 , wherein the killed Enterococcus faecalis is prepared as an ointment, a gel, or a cream.
15. 15 . The method according to claim 10 , wherein the killed Enterococcus faecalis is prepared as a liquid suspension.
16. 16 . The method according to claim 15 , wherein the liquid suspension comprises 0.6% by mass or more of the killed Enterococcus faecalis.
17. 17 . The method according to claim 15 , wherein the liquid suspension further comprises at least one selected from the group consisting of glycerin, caprylic acid monoglyceride, ethanol, and purified water.
18. 18 . The method according to claim 15 , wherein the liquid suspension is used as a spray.
19. 19 . The method according to claim 15 , wherein the liquid suspension is soaked in an absorbent material to prepare a sanitizing wipe.
20. 20 . The method according to claim 10 , wherein the killed Enterococcus faecalis is EF-2001 strain.

Description

TECHNICAL FIELD The present invention relates to a growth inhibitor for Clostridioides (Clostridium) difficile. BACKGROUND ART Clostridioides (Clostridium) difficile infections (CDIs) often occur when the gastrointestinal flora is disrupted by use of antibiotics or some other reason. In most cases, development of CDIs is associated with use of antibiotics. Further susceptibility factors for developing CDIs include aging and presence of underlying diseases. Most of CDIs are gastrointestinal infections, main symptoms of which are diarrhea and abdominal pain. CDIs are sometimes accompanied by fever and leukocytosis, occasionally leading to death due to toxic megacolon, ileus or gastrointestinal perforation if their symptoms become severer. There are “carriers” of Clostridioides difficile who carry C. difficile in the gastrointestinal tract but are asymptomatic. A large number of such “carriers” are found among hospitalized patients to whom antibiotics are frequently administered. C. difficile is discharged with the stool of CDI patients and asymptomatic carriers, contaminates the environment including the fingers of health care workers and medical staff, and causes a problem of health-care-associated infection. Therefore, CDI is a common infection in health care sites where a number of elderly persons who need excretion care (such as exchange of diapers) are hospitalized and yet infection control (including appropriate use of antibiotics) is not adequately performed. However, in those medical institutions where antibiotics are abused or infection control is inadequate, the levels of concern and knowledge about CDI are so low that it often occurs that the disease is not diagnosed appropriately and its incidence seems apparently low: this is indeed a problematic situation. Thus, medical institutions and elderly care facilities are in an environment where CDI easily becomes chronic and this had led to a discussion about the necessity for taking infection control measures. PRIOR ART LITERATURE Non-Patent Documents Non-Patent Document No. 1: Basic science and clinical aspect of C. difficile infection, Modern Media Vol. 56, No. 10, 2010 www.eiken.co.jp/modern_media/backnumber/pdf/MM1010_01.pdf DISCLOSURE OF THE INVENTION Problem for Solution by the Invention It is an object of the present invention to provide a growth inhibitor for Clostridioides difficile. Means to Solve the Problem As a result of intensive efforts, the present inventors have found that killed Enterococcus faecalis can inhibit the growth of Clostridioides difficile; the present invention has been achieved based on this finding. The gist of the present invention is as follows. (1) A growth inhibitor for Clostridioides difficile, comprising killed Enterococcus faecalis. (2) A parenteral pharmaceutical preparation for inhibiting the growth of Clostridioides difficile, comprising killed Enterococcus faecalis. (3) A bactericide, disinfectant, antibacterial agent, sanitizer or detergent for inhibiting the growth of Clostridioides difficile, comprising killed Enterococcus faecalis. (4) A medicine for external use, comprising killed Enterococcus faecalis. (5) A hygiene product comprising killed Enterococcus faecalis. Effect of the Invention The present invention enables inhibition of the growth of Clostridioides difficile. The present specification encompasses the contents of the specification and/or drawings disclosed in Japanese Patent Application No. 2020-43740 based on which the present application claims priority. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows test results (viable cell count (×103 CFU/ml)) in Example 1. ○: Control group: □: Low concentration group (test substance concentration: 0.64 mg/ml); Δ: high concentration group (test substance concentration: 64 mg/ml). Significant difference compared with the control group (**: p<0.01). BEST MODES FOR CARRYING OUT THE INVENTION Hereinafter, embodiments of the present invention will be described in more detail. The present invention provides a growth inhibitor for Clostridioides difficile, comprising killed Enterococcus faecalis. The present invention also provides a method of inhibiting the growth of Clostridioides difficile, comprising using killed Enterococcus faecalis. Further, the present invention provides drugs comprising killed Enterococcus faecalis, for use in a method of inhibiting the growth of Clostridioides difficile. Enterococcus faecalis is known as a lactic acid coccal bacterium having biological response modifier (BRM) activity (YAKUGAKU ZASSHI, 112:919-925, 1992; YAKUGAKU ZASSHI, 113:396-399, 1992; Journal of Animal Clinical Research, 3:11-20, 1994). Enterococcus faecalis EF-2001 strain is available from Nihon Berumu Co., Ltd. (2-14-3 Nagatacho, Chiyoda-ku, Tokyo). Enterococcus Faecalis-2001 strain can be obtained from the stool of a normal person and has the following properties. A Gram-positive coccus. Shape of colony (Trypto-Soya agar medium, 24-hour culture): 1.0-mm diamete